Literature DB >> 9098306

Initial management and follow-up of melanocytic iris tumors.

J W Harbour1, J J Augsburger, R C Eagle.   

Abstract

PURPOSES: To identify clinical variables prognostic for prompt excision of melanocytic iris tumors and to determine the clinical factors predictive of enlargement of those tumors managed initially by observation.
METHODS: A retrospective study of 285 patients evaluated in a referral center over a 15-year interval (1972-1986).
RESULTS: Thirty-six lesions were excised promptly, whereas 249 were observed. Eighty-nine percent of the 36 promptly excised tumors were malignant melanomas on histopathologic examination. Five clinical variables were associated strongly with prompt excision: largest basal tumor diameter greater than 3 mm; presence of pigment dispersion; prominent tumor vascularity; elevated intraocular pressure; and tumor-related ocular symptoms. In the observed group, the actuarial 5-year rate of lesion enlargement was 6.5% (standard error = 2.1%). Of the ten lesions that enlarged, six were excised and evaluated histopathologically. Five of these six lesions were malignant melanomas on histopathologic study. Largest basal tumor diameter was the only clinical variable strongly predictive of lesion enlargement. Only two patients died of metastatic uveal melanoma, and both were in the promptly treated group.
CONCLUSIONS: Most melanocytic iris tumors are benign and do not enlarge appreciably when followed or lead to metastatic disease. However, even prompt locally effective treatment (excision) is insufficient to prevent metastasis in some patients. Clinical features of the iris lesion appear to enable clinicians to differentiate reasonably well between probable malignant melanomas, for which prompt treatment seems appropriate, and benign nevi, for which observation with periodic follow-up is likely to be the best management.

Entities:  

Mesh:

Year:  1995        PMID: 9098306     DOI: 10.1016/s0161-6420(95)30765-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  9 in total

Review 1.  Don't it make my blue eyes brown: heterochromia and other abnormalities of the iris.

Authors:  I G Rennie
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

2.  Plaque radiotherapy treatment with ruthenium-106 for iris malignant melanoma.

Authors:  M Tsimpida; J Hungerford; A Arora; V Cohen
Journal:  Eye (Lond)       Date:  2011-09-23       Impact factor: 3.775

3.  Primary iris melanoma: diagnostic features and outcome of conservative surgical treatment.

Authors:  R M Conway; W C Chua; C Qureshi; F A Billson
Journal:  Br J Ophthalmol       Date:  2001-07       Impact factor: 4.638

Review 4.  An update on ophthalmological perspectives in oculodermal melanocytosis (Nevus of Ota).

Authors:  Solmaz Abdolrahimzadeh; Damiano Maria Pugi; Priscilla Manni; Clemente Maria Iodice; Federico Di Tizio; Flavia Persechino; Gianluca Scuderi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-07-19       Impact factor: 3.535

5.  Gene expressing profiling of iris melanomas.

Authors:  J William Harbour; David Wilson; Paul T Finger; Lori A Worley; Michael D Onken
Journal:  Ophthalmology       Date:  2013-01       Impact factor: 12.079

6.  Proton beam therapy for presumed and confirmed iris melanomas: a review of 36 cases.

Authors:  Ahmed Rahmi; Hamid Mammar; Juliette Thariat; Gaelle Angellier; Joel Herault; Pierre Chauvel; Laurent Kodjikian; Philippe Denis; Jean Daniel Grange
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-20       Impact factor: 3.117

7.  Enucleation in malignant choroidal melanoma - results in 15 years of using a new material in the prosthesis of the orbital cavity.

Authors:  C P Tataru; M D Pop
Journal:  J Med Life       Date:  2012-06-18

8.  Evaluation of Iris Melanoma with Anterior Segment Optical Coherence Tomography.

Authors:  Mehtap Arslantürk Eren; Ahmet Kaan Gündüz; Özlenen Ömür Gündüz
Journal:  Turk J Ophthalmol       Date:  2017-08-15

9.  [Relative contraindication of latanoprost in iris tumors with secondary glaucoma].

Authors:  S J Fröhlich; A J Mueller; A Kampik
Journal:  Ophthalmologe       Date:  2003-08       Impact factor: 1.059

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.